{"id":16750,"date":"2023-03-22T14:55:20","date_gmt":"2023-03-22T14:55:20","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/cybersecurity-arms-race\/"},"modified":"2023-03-22T14:55:20","modified_gmt":"2023-03-22T14:55:20","slug":"cybersecurity-arms-race","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/","title":{"rendered":"Cybersecurity: arms race?"},"content":{"rendered":"<p>The risks associated with c<strong>yber threats and data loss are a priority for companies in the pharmaceutical sector.<\/strong> Despite efforts to defend oneself, however, it is difficult to keep up to date and keep up with ever-new and ever-increasing dangers. British cybersecurity services provider <a href=\"https:\/\/riskxchange.co\/2022-pharma-industry-cybersecurity-report\/\" target=\"_blank\" rel=\"noopener\">Riskxchange<\/a> conducted a <strong>risk assessment of the 100 largest pharmaceutical companies by revenue<\/strong>, showing how the sector coped from April 2021 to April 2022.<\/p>\n<h1>Ever-increasing threats<\/h1>\n<p>The analysis takes into consideration different types of cyber threats. Regarding <strong>network security<\/strong>, first of all, <strong>data breaches are very common<\/strong>, especially considering that they do not necessarily have to affect the company directly. Violations by suppliers or third parties can also cause costly damage. According to IBM, t<strong>he average cost for a data breach in the pharmaceutical industry in 2021 was approximately $5.04 million.<\/strong><\/p>\n<p><strong>Ransomeware<\/strong> is even more harmful. Due to programs that block access to networks or parts of them and then demand a ransom, companies can go out of business. According to Riskxchange itself, in 2021 <strong>one in ten multinational pharmaceutical companies was at risk of suffering this type of attack<\/strong>. Less radical but still harmful is <strong>phishing<\/strong>, where one is robbed of critical information from apparently reliable sources. <strong>This type of attack is on the increase<\/strong> and according to the digital services company Verizon in 2021, 36% of data breaches occurred using this technique.<\/p>\n<p>Furthermore, the recent development of the so-called <strong>Internet of Things<\/strong> combines the undisputed advantages of new fragilities. In fact, the integration between networks and systems <strong>increases the surface area vulnerable to cyber attacks<\/strong>. Finally, among the causes that lead to cybersecurity violations, one surpasses all others: <strong>human error<\/strong>. In fact, workers were the primary vehicle for data breaches across all industries in 2021, as Verizon reports.<\/p>\n<h2>Cybersecurity: where are we at?<\/h2>\n<p>The distribution of cybersecurity problems in the pharmaceutical sector sees the poor reliability of networks and applications at the forefront. In particular, 35% of the problems encountered concern the scarcity of the security network and <strong>firewall policies<\/strong>, while 34% concern applications and <strong>configuration management<\/strong>.<\/p>\n<p>Furthermore, the analysis found several points where networks may be vulnerable to cyber attacks. In fact, 15% of the problems found concern the <strong>security of databases<\/strong>, sometimes published on the Internet without protection, while in 10% of cases low-level encryption or even its total absence was detected. Only 5% of the problems concern the poor security of emails and <strong>Domain Name System<\/strong> (DNS), which opens the door to phishing.<\/p>\n<p>Finally, in one of the companies analyzed, the company discovered the presence of <strong>malware<\/strong> distributed within the company systems during the analysis.<\/p>\n<h2>The performance of companies<\/h2>\n<p>Continuing the data analysis, Riskxchange highlights how 37% of cybersecurity issues concern the Internet or the <strong>security of corporate networks<\/strong>. Furthermore, in 14% of cases, the problem is so critical that it could allow a <strong>hacker<\/strong> to access company data and systems. Regarding encryption and configuration processes, the situation is insufficient in 27% of companies, with 21% of systems featuring low-level <strong>cryptographic encryption<\/strong>. Furthermore, in 36% of cases web applications have a poor security configuration, in 31% applications <strong>have obsolete TLS<\/strong> (Transport Layer Security) versions and in 30% the SSL (Secure Sockets Layer) encryption certificates have expired.<\/p>\n<p>Riskxchange then assigned a score to each company&#8217;s security level. No one reached the maximum score and the average value was 745\/900. The best company scored 864 points, while many companies fell below 700, with the worst achieving a score of 634. According to Riskxchange, such a <strong>score exposes a company to a serious data breach event within the 12 months.<\/strong><\/p>\n<p><strong>The global trend is worsening compared to previous years<\/strong>. Furthermore, in 57% of cases the problems encountered were <strong>highlighted as early as 2017<\/strong>. Companies therefore appear to have been unable to keep up with the vulnerabilities found and resolve any problems in time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.<\/p>\n","protected":false},"author":18,"featured_media":15496,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[840],"tags":[936,935],"class_list":{"0":"post-16750","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-security-and-privacy","8":"tag-data-protection-en","9":"tag-safety-en"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cybersecurity: arms race? - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cybersecurity: arms race? - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T14:55:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1316\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Valentina Guidi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Guidi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\"},\"author\":{\"name\":\"Valentina Guidi\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/23cf85ce50fdc96ea35c11e493453f17\"},\"headline\":\"Cybersecurity: arms race?\",\"datePublished\":\"2023-03-22T14:55:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\"},\"wordCount\":615,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg\",\"keywords\":[\"data protection\",\"safety\"],\"articleSection\":[\"Security and privacy\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\",\"name\":\"Cybersecurity: arms race? - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg\",\"datePublished\":\"2023-03-22T14:55:20+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/23cf85ce50fdc96ea35c11e493453f17\"},\"description\":\"The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg\",\"width\":1920,\"height\":1316},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cybersecurity: arms race?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/23cf85ce50fdc96ea35c11e493453f17\",\"name\":\"Valentina Guidi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/8db00172a47b891ea004b807b8f67446fec292a4a7a8bdcbd7e1fdee616d9e9f?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8db00172a47b891ea004b807b8f67446fec292a4a7a8bdcbd7e1fdee616d9e9f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8db00172a47b891ea004b807b8f67446fec292a4a7a8bdcbd7e1fdee616d9e9f?s=96&d=mm&r=g\",\"caption\":\"Valentina Guidi\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-guidi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cybersecurity: arms race? - MakingPharmaIndustry","description":"The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/","og_locale":"en_US","og_type":"article","og_title":"Cybersecurity: arms race? - MakingPharmaIndustry","og_description":"The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.","og_url":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2023-03-22T14:55:20+00:00","og_image":[{"width":1920,"height":1316,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg","type":"image\/jpeg"}],"author":"Valentina Guidi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Guidi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/"},"author":{"name":"Valentina Guidi","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/23cf85ce50fdc96ea35c11e493453f17"},"headline":"Cybersecurity: arms race?","datePublished":"2023-03-22T14:55:20+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/"},"wordCount":615,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg","keywords":["data protection","safety"],"articleSection":["Security and privacy"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/","url":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/","name":"Cybersecurity: arms race? - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg","datePublished":"2023-03-22T14:55:20+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/23cf85ce50fdc96ea35c11e493453f17"},"description":"The English cybersecurity services provider Riskxchange has analyzed the cybersecurity of the pharmaceutical sector, highlighting several shortcomings.","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/03\/circle-g3a4d8a69b_1920.jpg","width":1920,"height":1316},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/supply-chian\/security-and-privacy\/cybersecurity-arms-race\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Cybersecurity: arms race?"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/23cf85ce50fdc96ea35c11e493453f17","name":"Valentina Guidi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8db00172a47b891ea004b807b8f67446fec292a4a7a8bdcbd7e1fdee616d9e9f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8db00172a47b891ea004b807b8f67446fec292a4a7a8bdcbd7e1fdee616d9e9f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8db00172a47b891ea004b807b8f67446fec292a4a7a8bdcbd7e1fdee616d9e9f?s=96&d=mm&r=g","caption":"Valentina Guidi"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-guidi\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/16750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=16750"}],"version-history":[{"count":0,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/16750\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/15496"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=16750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=16750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=16750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}